Clinical trials · Washington, D.C., DC
Cancer clinical trials in Washington, D.C.
We’re tracking 953 recruiting cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT04717349Recruiting
Study collects health information for kids’ and teens’ gynecology concerns
This is a research study that gathers information about pediatric and adolescent gynecology conditions. It may help researchers better understand these issues by learning about symptoms, care, and outcomes—without requiring a specific treatment.
Bethesda, MarylandAges 1 day–100 years - NCT04888936Recruiting
Study families with genetic RAS syndromes, including adults and children
This study looks at people with certain inherited genetic conditions called RASopathies and their family members. It helps researchers understand these conditions and how genetic changes run in families, which may improve future care.
Bethesda, MarylandAges 1 month–99 years - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Bethesda, MarylandAges 18 years+ - NCT04968288Recruiting
Study of the natural course of KSHV-related Castleman disease
This study looks at how KSHV-associated multicentric Castleman disease naturally progresses over time, without necessarily testing a new treatment. It may help doctors better understand the disease and what changes to watch for, which could guide future care.
Bethesda, MarylandAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Bethesda, MarylandAges 18–59 - NCT04941274RecruitingPhase 1/Phase 2
Abemaciclib for Kaposi sarcoma in people with or without HIV
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
Bethesda, MarylandAges 18–99 - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Bethesda, MarylandAges 12 years+ - NCT06161506RecruitingPhase 2
Electrical stimulation for urinary incontinence after prostate cancer treatment
This trial tests a non-surgical, non-drug treatment that uses gentle electrical stimulation on the skin to help strengthen the muscles that control urine leakage. It's for men who still have urinary incontinence at least 6 months after their prostate cancer treatment.
Bethesda, MarylandAges 18–120 - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Bethesda, MarylandAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT06995872RecruitingPhase 1
Study of rhIL-15 with immunotherapy and chemo for neuroblastoma
This trial tests a new combination of drugs (rhIL-15, dinutuximab, irinotecan, and temozolomide) for children and young adults whose neuroblastoma has come back or hasn't responded to other treatments. The goal is to see if this mix can help shrink or control the cancer.
Bethesda, MarylandAges 3–35 - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after stem cell transplant for high-risk blood cancer
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
Bethesda, MarylandAges 12–120 - NCT05350748Recruiting
MDS study using detailed tests on blood and bone marrow
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
Bethesda, MarylandAges 1 day–120 years - NCT05361798RecruitingPhase 2
Testing immune response after prostate radiation with or without a drug
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
Bethesda, MarylandAges 18 years+ - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Bethesda, MarylandAges 18–120 - NCT07019155Recruiting
DDX41 gene study for families with cancer risk
This study looks at people and families who have changes in the DDX41 gene or similar genes that may increase the risk of cancer. By joining, you can help researchers learn more about these gene changes and how they affect health.
Bethesda, MarylandAges 1 month–120 years - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15–99 - NCT06965114RecruitingPhase 1/Phase 2
Testing tovorafenib plus rituximab for hairy cell leukemia
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
Bethesda, MarylandAges 18 years+ - NCT05600933Enrolling by invitation
Providing tumor samples to find new treatment targets
This study collects tumor tissue and related blood tests from people who already need a biopsy or surgery as part of their usual care. Researchers use the samples to learn what drives the tumor and how the tumor environment may affect treatment, which could help develop future therapies.
Bethesda, MarylandAges 18 years+ - NCT05588154Recruiting
Donate blood and other samples to study blood cancers
This study asks healthy adults to provide blood, bone marrow (if needed), skin, saliva, and stool samples. Scientists use these samples to compare patterns related to myeloid (bone-marrow) blood cancers, which may help future research and tests.
Bethesda, MarylandAges 18–120
Hear when a new Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting cancer studies listed above.
- National Institutes of Health Clinical Center · 20 studies
- Center for Cancer and Blood Disorders
- Inova Fairfax Hospital
- Inova Schar Cancer Institute
- Johns Hopkins Hospital
- National Cancer Institute - Shady Grove
- NCI Center for Cancer Research
- Research Site
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in District of Columbia.
Common questions
- Are there cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 953 recruiting cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.